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Mutation in p53 (TP53) remains one of the most commonly described genetic events in human
neoplasia. The occurrence of mutations is somewhat less common in sporadic breast carcinomas than in
other cancers, with an overall frequency of about 20%. There is, however, evidence that p53 is mutated at
a significantly higher frequency in breast carcinomas arising in carriers of germ-line BRCA1 and BRCA2
mutations. Some of the p53 mutants identified in BRCA1 and BRCA2 mutation carriers are either
previously undescribed or infrequently reported in sporadic human cancers. Functional characterization
of such mutants in various systems has revealed that they frequently possess properties not commonly
associated with those occurring in sporadic cases: they retain apoptosis-inducing, transactivating, and
growth-inhibitory activities similar to the wild-type protein, yet are compromised for transformation
suppression and also possess an independent transforming phenotype. The occurrence of such mutants in
familial breast cancer implies the operation of distinct selective pressures during tumorigenesis in BRCA-
associated breast cancers. Hum Mutat 21:301–306, 2003. r 2003 Wiley-Liss, Inc.
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INTRODUCTION
The p53 gene (TP53; MIM# 191170) is one of the
most commonly mutated genes thus far described in
human neoplasia, with mutations estimated to occur
in up to 50% of all cancers. Mutations are principally,
but not exclusively, missense. The majority of mutant
proteins are defective for sequence-specific DNA
binding and transactivation of p53-responsive genes,
and some have acquired dominant transforming
activity [Ko and Prives, 1996; Sigal and Rotter, 2000].
The status of p53 in human breast cancer has been
the subject of intensive investigation [reviewed in
Gasco et al., 2002; Borresen-Dale, 2003]. The
presence of mutation, with or without accompanying
loss of heterozygosity (LOH), was an early finding in
cell lines and primary breast cancers, establishing p53
as a bona fide tumor suppressor gene in the breast.
Breast carcinomas are also a recognized clinical
feature in Li Fraumeni syndrome (LFS; MIM#
151623), in which germ-line carriage of p53 mutation
predisposes to an increased incidence of several
cancers. However, whereas p53 is mutated at a high
frequency in several common human solid tumors, the
frequency of mutation in sporadic breast cancer is
substantially lower [Pharoah et al., 1999]. Specific
forms of the disease appear, however, to be associated
with a higher frequency of p53 mutations. These
include cancers arising in germ-line carriers of BRCA1
(MIM# 113705) and BRCA2 (MIM# 600185)
mutations and typical medullary breast cancers,
which share a number of pathobiological features
with BRCA1-associated cases [de Cremoux et al.,
1999].
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BRCA1/BRCA2 INSUFFICIENCY MAYACTIVATE
TP53-DEPENDENTCHECKPOINTS
Germ-line mutations in the breast cancer suscept-
ibility genes BRCA1 and BRCA2 confer a substan-
tially increased risk of breast cancer [Miki et al., 1994;
Wooster et al., 1995]. Following the cloning of
BRCA1, attempts were made to generate knock-out
mice. These experiments were unsuccessful, embryo-
nic death occurring before day 7.5 due to growth
arrest associated with up-regulation of expression of
p21Waf1 and down-regulation of mdm2 [Hakem et al.,
1996]. Subsequently, it was shown that this phenotype
could be partially reversed by crossing into mouse
strains carrying null mutations in p53 or p21Waf1
[Hakem et al., 1997]. Like BRCA1 mutant mice,
deletion of exons 10 and 11 of BRCA2 results in death
during embryogenesis and this too was shown to be
associated with impaired cellular proliferation and up-
regulation of p21Waf1 [Suzuki et al., 1997]. These
studies thus revealed that loss of BRCA1 and/or
BRCA2 function results in a p21Waf1-mediated G1
growth arrest that is, at least in part, p53-dependent.
Using conditional knock-out of BRCA1 it has been
shown that breast tumorigenesis following induced
loss of BRCA1 requires a lengthy latent period, but
this is significantly reduced when the original line is
crossed into a p53 +/– strain [Xu et al., 1999].
Extrapolation of these findings to human breast
cancer suggested a simple model of tumorigenesis in
which it was hypothesized that loss of the wild-type
BRCA1/2 allele originally present in the cells of
carriers of mutant alleles of BRCA1 and BRCA2
would activate a p53-dependent checkpoint.
Abrogation of this checkpoint could be accomplished
by mutation in p53, resulting in expression of a
mutant protein lacking the ability to activate the
checkpoint.
ADISTINCT SPECTRUMOF TP53 MUTATIONS IN
BRCA-ASSOCIATEDCANCERS
Sequencing studies of p53 have demonstrated an
elevated frequency of mutation in BRCA1- and
BRCA2-associated breast cancers compared to
grade-matched sporadic cases [Crook et al., 1998;
Gretarsdottir et al., 1998; Phillips et al., 1999]. In
some BRCA1 and BRCA2 carcinomas several in-
dependent p53 mutations were detected, these
apparently targeting a single allele in certain cases
[Crook et al., 1998]. This is reminiscent of an earlier
study of familial breast cancers (of unknown BRCA
status), in which p53 was mutated at high frequency
and multiple mutations and novel p53 alleles occurred
commonly [Glebov et al., 1994]. One study has failed,
however, to detect an increased frequency in p53
mutation in BRCA1 cancers [Schlichtholz et al.,
1998]. Studies in ovarian carcinoma have also
reported an increased frequency of p53 mutation
[Ramus et al., 1999; Zweemer et al., 1999].
Taken together, the increased frequency of p53
mutations generally observed in BRCA-associated
cancers is consistent with the mechanistic models
adduced from studies of tumorigenesis in BRCA1
mutant mice.
It is now well recognized that p53 mutations in
sporadic human tumors preferentially target specific
codons. For example, 28% of such mutations occur in
codons 175, 245, 248, 249, 273, and 282 [Vousden
and Lu, 2002]. Other frequently mutated hot spot
codons have also been identified [Walker et al., 1999].
Analysis of breast cancers arising in BRCA1 and
BRCA2 germ-line mutation carriers revealed that a
significant proportion of p53 mutations occurred at
non-hot spot codons. Indeed, many mutations were
either previously undescribed or very uncommon in
human cancer [Crook et al., 1998]. A meticulous
review of the p53 mutations reported in the literature
has confirmed this and further identified some
intriguing and provocative conclusions [Greenblatt
et al., 2001]. First, of 73 mutations identified in
BRCA1/BRCA2 mutation carriers no less than 19 had
not been previously reported in breast cancer and nine
had never been described in any human cancer in the
IARC human p53 database (www.iarc.fr/p53/Home-
page.htm). Second, in contrast to most of the
commonly detected human tumor-associated p53
mutations, the novel non-hot spot mutations detected
in the BRCA-associated cancers are located on the
non-DNA binding side of p53. The occurrence of
CC4TT mutations at dipyrimidine sites in two
BRCA-associated breast cancers was another surpris-
ing finding in view of the rarity of such tandem
mutations in human cancer. Almost all (51/57)
previously described CC4TT mutations are in skin
cancer where they arise due to aberrant repair of
cyclobutane photoproducts. Of the six CC4TT
mutations which were detected in other cancers, five
are in breast or ovarian cancers, raising the possibility
that these may also have occurred in BRCA1/BRCA2
mutant cancers [Greenblatt et al., 2001]. Together,
the frequency and spectrum of p53 mutations
identified in these cancers supports the theory that
loss of BRCA1/BRCA2 DNA repair function facil-
itates the generation (and perhaps selection) of
somatic mutations which contribute to tumorigenesis
in the breast. A summary of the structural pro-
perties of p53 mutations in BRCA1- and BRCA2-
associated cancers is shown in Table 1 [Greenblatt
et al., 2001].
TRANSACTIVATING PROPERTIES OF BRCA-
ASSOCIATEDTP53 MUTANTS
The apparent concentration of previously unde-
scribed and/or extremely rare p53 mutants in
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independent series of BRCA-associated breast cancers
clearly merited their functional characterization. One
of the most important activities of wild-type p53 is its
ability to activate expression of downstream genes via
sequence-specific DNA binding and thereby to
modulate cellular responses such as apoptosis and cell
cycle arrest [Vogelstein et al., 2001]. In an initial
study, transactivating activity of the BRCA-associated
mutants was analyzed by over-expression in human
Saos-2 p53 –/– cells [Smith et al., 1999]. These
studies revealed that mutants which occurred at
recognized human tumor hot spots (158H, 163N,
168Y, 234C, and 248W) were significantly compro-
mised for sequence-specific DNA binding and trans-
activating activity (Table 2). These findings were
unsurprising, since loss of this activity is common to
the vast majority of human tumor-associated mutants.
Abrogation of p21Waf1 inducing activity also sup-
ported the model suggested by studies of BRCA1
mutant mice in which BRCA1 loss caused p21Waf1
dependent proliferation block. In contrast to the hot
spot mutants, however, a significant proportion of
non-hot spot mutants retained transactivating activity
close to that of the wild-type protein. In particular
three mutants, 150I, 199R, and 202S, were virtually
indistinguishable from wild-type p53 in assays of
transactivation of multiple promoters, including
p21Waf1 and the apoptosis-promoting genes Bax and
PIG3. This was an unexpected result, since previously
described ‘‘transactivation competent’’ mutants such
as 175P and 181L are able to activate expression of
genes such as p21Waf1 but are defective in activation
of apoptosis-inducing genes such as Bax [Crook et al.,
1994; Rowan et al., 1996]. Other BRCA-associated
mutants, for example 181C and 215C, also retain
wild-type activity in transactivation of some promoters
such as PIG3 (Table 2), but are defective for
transactivation of others such as Bax and IGF BP3
Box A [Smith et al., 1999]. The properties of these
BRCA-associated p53 mutants were further examined
in yeast assays by Campomenosi et al. [2001]. In these
studies, yeast strains were used which contained an
ADE gene whose promoter was regulated by the p53
responsive elements from the p21Waf1, PIG3, and Bax
genes. Consistent with the earlier of work of Smith
et al. [1999], the incidence of transcriptionally active
mutants is significantly higher than in a panel of
mutants derived from sporadic human tumors.
Furthermore, the incidence of fully transcriptionally
inactive mutants is significantly lower than in the
sporadic mutants: only 163N, 168Y, and 248W are
totally inactive with all promoters under all condi-
tions, whereas each of the remaining 10 mutants show
some promoter activation in at least one strain
[Campomenosi et al., 2001]. The activity exhibited
by 150I, 199R, 202S, and 215C was indistinguishable
from wild-type p53 in each of the yeast reporter
strains, consistent with analyses performed in human
cells [Smith et al., 1999].
Activation of p21Waf1 correlates well with p53-
dependent inhibition of proliferation of p53 null cells
such as Saos-2 and each of the BRCA-associated
mutants with wild-type or close to wild-type ability to
transactivate p21Waf1 efficiently suppressed Saos-2
growth [Smith et al., 1999]. The only exception to
TABLE 1.TP53 Mutation Spectrum in BRCA1- andBRCA2-Re-
lated and Sporadic Breast Carcinomas






A :T base pairs 38% 25%
TandemCC4TT 2% 0.1%
Multiple substitutions 16% 4%
Data derived fromGreenblatt et al. [2001].
TABLE 2. Properties ofTP53 Mutants fromBRCA1- andBRCA2-Associated Breast Carcinomas
Mutant Hotspot p21a p21b PIG3c PIG3d Apoptosise Transformationf
Wild-type N/A +++ + +++ + +++ ^
144P No ^ ^ ^ ^ ^ ++
150I No + + +++ + +++ +
158H Yes + +/^ ^ ^ + ++
163N Yes ^ ^ ^ ^ ^ +++
168Y Yes ^ ^ ^ ^ ^ +++
181C Yes +++ + +++ ^ ++ +
199R No +++ + +++ + +++ +
202S No +++ + +++ + +++ +
215C Yes +++ + +++ + ++ +
219H No + +/^ + +/^ ^ ++
248W Yes ^ ^ ^ ^ ^ +++
aTransactivation determined in Saos-2 human cells: +,20^50% of wild-type;+++,50^100% of wild-type.
bResults from yeast-based assay.+white colonies;+/, pink colonies;, red colonies. Results shown are from growth at 37oC.
cDetermined in Saos-2 cells.
dYeast-based assay.
eDetermined in Saos-2 cells.+,10^20% of wild-type; ++,20^50% of wild-type; +++,50^ 100% wild-type.
fDetermined in primary rat embryo ¢broblasts by co-transfectionwith activated ras. +,10^20% of positive control (173L);++,20^50% positive
control.
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this correlation was mutant 144P, which lacks
detectable ability to activate p21Waf1, yet was never-
theless shown to inhibit Saos-2 by 40–50%.
APOPTOSIS
Loss of apoptosis-inducing activity is a property
common to virtually all previously characterized
human tumor-associated p53 mutants [Ko and Prives,
1996]. The hot spot BRCA-associated mutants 158H,
163N, 168Y, and 248W, together with two non-hot
spot mutants 144P and 219H have only minimal
activity in assays of p53-dependent apoptosis assessed
by over-expression in Saos-2 cells (Table 2). In
contrast, mutants 150I, 199R, and 202S possess close
to wild-type activity, while 181C and 215C also retain
significant activity. Retention of apoptosis-inducing
activity by a significant proportion of the BRCA-
associated mutants is another unexpected finding, but
closely parallels their transactivating profiles.
TRANSDOMINANCE ANDTRANSFORMATION
Certain p53 mutants can trans-dominantly inhibit
wild-type p53 when the two forms of the protein are
co-expressed in the same cell. Examples of such
mutants include 245C, 248W, and 273H [Aurelio
et al., 2000]. Analysis in yeast of the BRCA1- and
BRCA2-associated p53 mutants for their ability to
inhibit wild-type p53 revealed that only the hot spot
mutants 163N, 168Y, and 248W efficiently inhibit
p53-dependent transactivation of Bax. All the mu-
tants that behaved like wild-type p53 in transactiva-
tion assays were always recessive to wild-type p53
[Monti et al., 2002]. The inability of these mutants to
inhibit wild-type p53 is interesting since these same
mutants all possess some independent transforming
activity in primary rodent cells. As such, these results
imply that transdominant inhibition of endogenous
p53 may not be an absolute requirement for in vitro
transforming activity. A similar conclusion was
reached in earlier analysis of mutants 175P and
181L, which have transforming phenotypes yet are
recessive to wild-type p53 [Crook et al., 1994]. It
should be noted, however, that the most potent
transforming mutants from the BRCA-associated
cancers, namely 163N, 168Y, and 248W, are those
which are dominant to p53 [Smith et al., 1999; Monti
et al., 2002]. One of the properties of wild-type p53 is
its ability to suppress in vitro transformation mediated
by co-operating oncogenes such as E1A and ras
[Finlay et al., 1989]. This activity is absent from each
of the BRCA-associated p53 proteins, supporting their
status as genuine mutants, although the functional
defect responsible for this cannot be definitively
identified from the presently available data [Smith
et al., 1999].
CONCLUSIONS
Transactivation-competent p53 proteins comprise
only about 20% of all detected mutants in human
cancers [Campomenosi et al., 2001]. However,
whereas such mutants are able to activate the
promoters of non-apoptotic genes such as p21Waf1,
they are invariably unable to activate expression of
apoptotic genes and, like virtually all human tumor-
associated mutants, are compromised for apoptosis
induction [Crook et al., 1994; Rowan et al., 1996;
Campomenosi et al., 2001]. The occurrence of
apparently fully transactivation- and apoptosis-com-
petent mutants in BRCA1- and BRCA2-associated
breast cancers is therefore most unexpected and
raises the questions: What is the mechanistic
basis for their selection in cancer and why is their
presence in human cancer restricted to BRCA-
associated cases?
One obvious possible answer to the first question is
that the mutants are compromised in their ability to
transactivate genes whose p53-responsive elements
have not yet been functionally tested. The promoters
of p53-responsive genes exhibit considerable hetero-
geneity with respect to their inducibility by wild-type
p53. Furthermore, p53 target genes whose transcrip-
tional regulatory elements contain low-affinity p53
binding sites may require additional events for
activation [Szak et al., 2001]. Models of p53 action
propose that the promoters of apoptotic genes are
generally of lower affinity than those of genes such as
p21Waf1, which function in cell-cycle arrest. Numer-
ous effector proteins of p53-dependent apoptosis such
as p53AIP1, PUMA, Apaf1, NOXA have been
described [Vousden and Lu, 2002] but the inducibility
of these by BRCA-associated p53 mutants has not
been determined. It is therefore an interesting
possibility that the apparently wild-type BRCA-
associated mutants are in fact functionally compro-
mised for activation of other p53-responsive genes.
Recent evidence shows that this may indeed be the
case. Testing of the mutants in a panel of yeast strains
containing p53-responsive elements from a large
number of p53-inducible genes has revealed subtle
transactivating defects in each of the mutants
previously considered to have a fully wild-type
transactivating phenotype [Inga et al., 2002]. Further
characterization of multiple p53-responsive promoters
in such systems will clearly be of considerable interest
and may allow identification of p53-inducible genes
functioning in transformation suppression. Another
interesting and perhaps related possibility is that the
BRCA-associated p53 mutants are compromised in
their ability to interact with transcriptional co-
activators of p53. Again, there is preliminary evidence
to support this possibility. The ASPP family of proteins
(apoptosis-stimulating proteins of p53) selectively
activate the apoptosis-inducing function of p53
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[Samuels-Lev et al., 2001]. Amino acid 181 of p53 is
involved in protein–protein interaction with ASPP1
and the 181C mutant detected in two cases of BRCA-
associated breast cancer binds less efficiently to
ASPP1 than wild-type p53. The 181C protein is,
therefore, insensitive to the apoptosis-promoting
effects of the ASPP proteins suggesting a potential
mechanism for selection of 181C in BRCA-associated
cancers.
It is worth pointing out that apoptosis-inducing
activity of the BRCA-associated mutants was deter-
mined in our original studies simply by transient over-
expression of p53 protein from CMV-based eukaryotic
expression vectors in Saos-2 cells [Smith et al., 1999].
The effect of p53-activating stimuli such as DNA
damage, hypoxia, and deregulated E2F on the
apoptosis-inducing function of the mutants was not,
therefore, assessed. More recent studies in breast cells
engineered to inducibly express some of the mutants
originally designated as having fully wild-type proper-
ties, has revealed defective apoptosis induction and
aberrant phosphorylation in response to specific p53-
activating stimuli (unpublished observations). Such
systems may therefore be more sensitive and appro-
priate for the detection of these subtle differences
than those utilizing p53 over-expression.
Why then should such distinctive mutants only
occur in BRCA-associated cancers? Perhaps the
genetic background arising in BRCA null cells allows
the selection of p53 mutants possessing properties
whose expression cannot be tolerated in cells with
intact BRCA1 (and/or BRCA2). One clue may come
from the interaction of BRCA1 with wild-type p53.
Full-length BRCA1 protein associates with wild-type
p53 and is able to increase transcription from p53-
dependent promoters such as p21Waf1 and Bax [Zhang
et al., 1998]. Tumor-derived mutants of BRCA1 are
defective for transcriptional co-activation of p53, and
truncation mutants of BRCA1 retaining the p53
interaction domain can function as dominant–nega-
tive inhibitors of p53. In cancers arising in germ-line
carriers of BRCA mutations, the co-activating effect
of BRCA1 is absent. In this situation, the transacti-
vating activity of mutants such as 150I, 199R, 202S is
likely to be attenuated allowing their expression to be
tolerated. The subtle functional changes in such
mutants, as evidenced by their loss of transformation
suppression and gain of independent transforming
activity, may then be sufficient to confer selective
advantage.
It is an interesting possibility that the BRCA-
associated mutants represent the minimal loss of
function required to lose p53-dependent tumor
suppression. Further detailed characterization and
identification of the subtle defects they harbor may
provide valuable insights into the functions of p53
mediating suppression of transformation and tumor-
igenesis.
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